Cost-utility analysis of multiple sclerosis rehabilitation in Iran

References

• Gourraud PA, Harbo HF, Hauser SL, et al. The genetics of multiple sclerosis: an up‐to‐date review. Immunol Rev. 2012;248(1):87–103. doi: 10.1111/j.1600-065X.2012.01134.x
   PubMed Web of Science ®Google Scholar
• Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi: 10.1177/1352458520970841
   PubMed Web of Science ®Google Scholar
• Mirmosayyeb O, Shaygannejad V, Bagherieh S, et al. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. Neurol Sci. 2022;43(1):233–241. doi: 10.1007/s10072-021-05750-w
   PubMed Web of Science ®Google Scholar
• Compston A. Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;62(6):553. doi: 10.1136/jnnp.62.6.553
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700–722. doi: 10.1111/j.1468-1331.2006.01342.x
   PubMed Web of Science ®Google Scholar
• Williams R, Rigby AS, Airey M, et al. Multiple sclerosis: it epidemiological, genetic, and health care impact. J Epidemiol Community Health. 1995;49(6):563. doi: 10.1136/jech.49.6.563
   PubMed Web of Science ®Google Scholar
• Zuvich RL, McCauley JL, Pericak-Vance MA, et al. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009 Dec;21(6):328–33. doi: 10.1016/j.smim.2009.08.003. Epub 2009 Sep 22. PMID: 19775910; PMCID: PMC2789848 .
   Google Scholar
• Izadi S, Nikseresht A, Poursadeghfard M. Epidemiology of multiple sclerosis in Fars Province. Iran J Epidemiol. 2014;10(2):56–61.
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler J. 2012;18(2_suppl):7–15. doi: 10.1177/1352458512441566
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7(2):96–104. doi: 10.1007/s10198-006-0380-z
   Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23(8):1123–1136. doi: 10.1177/1352458517694432
   PubMed Web of Science ®Google Scholar
• Group IMSS. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial. Neurology. 1993;43(4):655–. doi: 10.1212/WNL.43.4.655
   PubMed Web of Science ®Google Scholar
• Asadollahi M, Darvishi A, Azimi A, et al. Economic burden of multiple sclerosis Drugs in Iran during 2011-2019. Iran J Public Health. 2023;52(2):407–419. doi: 10.18502/ijph.v52i2.11894
   PubMed Web of Science ®Google Scholar
• Asadollahi M, Darvishi A, Azimi A, et al. Estimation the medical cost of multiple sclerosis in Iran; 2019–2020. BMC Health Serv Res. 2022;22(1):137. doi: 10.1186/s12913-022-07551-z
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA, et al. Multiple sclerosis. N Engl J Med. 2018;378(2):169–180. doi: 10.1056/NEJMra1401483
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285. doi: 10.1016/S1474-4422(18)30443-5
   PubMed Web of Science ®Google Scholar
• Ghanati E, Hadiyan M, Asli AD. Economic expenditures of multiple sclerosis medications and feasibility of providing health insurance policies for medications. J Health Adm (JHA). 2011;14(45):37–54.
   Google Scholar
• Pazokian M, Shaban M, Zakerimoghdam M, et al. A comparison between the effect of stretching with aerobic and aerobic exercises on fatigue level in multiple sclerosis patients. Qom Univ Med Sci J. 2013;7(1):50–56.
   Google Scholar
• National Collaborating Centre for Chronic Conditions (UK). Multiple Sclerosis: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London, UK: Royal College of Physicians; 2004. PMID: 21290636.
   Google Scholar
• Perry M, Swain S, Kemmis-Betty S, et al. Multiple sclerosis: summary of NICE guidance. BMJ. 2014;349(oct08 10):g5701–g5701. doi: 10.1136/bmj.g5701
   PubMedGoogle Scholar
• Groppo E, Signori A, Sormani MP, et al. Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. Mult Scler J Exp Transl Sci. 2019;5(2):2055217319843673. doi: 10.1177/2055217319843673
   Web of Science ®Google Scholar
• Pappalardo A, D’Amico E, Leone C, et al. Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Mult Scler Demyelinating Disord. 2016;1(1):1–7. doi: 10.1186/s40893-016-0005-z
   Google Scholar
• McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Multi Sclerosis Relat Disord. 2019;29:55–61. doi: 10.1016/j.msard.2018.12.040
   PubMed Web of Science ®Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073. doi: 10.1136/bmjopen-2013-004073
   PubMed Web of Science ®Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–1024. doi: 10.1212/WNL.0000000000000768
   PubMed Web of Science ®Google Scholar
• Jick S, Li L, Falcone G, et al. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol. 2014;261(8):1508–1517. doi: 10.1007/s00415-014-7370-3
   PubMed Web of Science ®Google Scholar
• Fogarty E, Walsh C, Adams R, et al. Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Mult Scler J. 2013;19(9):1190–1196. doi: 10.1177/1352458512474860
   PubMed Web of Science ®Google Scholar
• Bank W GDP per capita (current US$) - Iran, Islamic Rep. World Bank national accounts data, and OECD National Accounts data files. 2021 [ Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IR.
   Google Scholar
• Boesen F, Nørgaard M, Skjerbæk AG, et al. Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term–the Danish MS hospitals rehabilitation study. Mult Scler J. 2020;26(14):1953–1957. doi: 10.1177/1352458519884244
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Williams H, Bill A, et al. Cost-efficiency of specialist inpatient rehabilitation for working-aged adults with complex neurological disabilities: a multicentre cohort analysis of a national clinical data set. BMJ Open. 2016;6(2):e010238. doi: 10.1136/bmjopen-2015-010238
   PubMed Web of Science ®Google Scholar
• Juckes F, Marceniuk G, Seary C, et al. A cohort study of functional electrical stimulation in people with multiple sclerosis demonstrating improvements in quality of life and cost-effectiveness. Clin Rehabilitat. 2019;33(7):1163–1170. doi: 10.1177/0269215519837326
   PubMed Web of Science ®Google Scholar
• Ponzio M, Gerzeli S, Brichetto G, et al. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci. 2015;36(2):227–234. doi: 10.1007/s10072-014-1925-z
   PubMed Web of Science ®Google Scholar